Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.
Guidelines on managing infants after initial anti-vascular endothelial growth factor (VEGF) treatment (eg, bevacizumab) for retinopathy of prematurity (ROP) are limited. We found that following initial bevacizumab treatment for ROP, prophylactically lasering infant eyes before hospital discharge reduced the number and duration of outpatient ROP screening examinations compared with following infants, per current United States (US) ROP screening guidelines.
Hong, GJ; Stinnett, SS; Freedman, SF; Wallace, DK; Prakalapakorn, SG
Volume / Issue
Start / End Page
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)